证券代码：300253 证券简称：卫宁健康 公告编号：2025-064 卫宁健康科技集团股份有限公司 第六届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日在公司会议室以现场和通讯表决方式召开第六届监事会第 十四次会议。会议通知于 2025 年 8 月 11 日以专人送达及电子邮件方 式发出。会议应出席监事 3 人，实际出席监事 3 人。会议由监事会主 席李琳女士主持。本次监事会的召集和召开符合《中华人民共和国公 司法》和《公司章程》的规定。经全体监事表决，形成决议如下： 一、会议以 3 票同意、0 票反对、0 票弃权的结果审议通过了《关 于<公司 2025 年半年度报告及其摘要>的议案》； 经审议，监事会认为：董事会编制和审核公司 2025 年半年度报 告及其摘要的程序符合法律、行政法规和中国证监会的规定，报告内 容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。 《2025 年半年度报告》《2025 年半年度报 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-063 卫宁健康科技集团股份有限公司 第六届董事会第十六次会议决议公告 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日在公司会议室以现场和通讯相结合的表决方式召开了第 六届董事会第十六次会议。会议通知于 2025 年 8 月 11 日以专人送达 或电子邮件方式发出。会议应出席董事 7 人，实际出席董事 7 人。本 次董事会的召集和召开符合《中华人民共和国公司法》和《公司章程》 的规定。会议由董事长周炜主持，公司监事及高级管理人员列席了本 次董事会。经全体董事表决，形成决议如下： 一、会议以 7 票同意、0 票反对、0 票弃权的结果审议通过了《关 于<公司 2025 年半年度报告及其摘要>的议案》； 经审议，董事会认为：公司编制的 2025 年半年度报告全文及摘 要真实、准确、完整地反映了公司 2025 年半年度的财务状况和经营 成果，不存在虚假记载、误导性陈述或重大遗漏。 本议案在提交董事会审议前已经公司第六届董事会审计委员会 第八次会议审议通过。 《2025 年半年度报告》《2025 年半年度报告摘要》同日披 ...

卫宁健康科技集团股份有限公司 2025 年半年度报告全文 卫宁健康科技集团股份有限公司 2025 年半年度报告 2025 年 8 月 1 卫宁健康科技集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人周炜、主管会计工作负责人王利及会计机构负责人(会计主管 人员)陈旭纹声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中所涉及的未来计划、发展战略等前瞻性描述，并不代表公司的 盈利预测，不构成公司对任何投资者及相关人士的实质承诺，也不构成对任 何人的投资建议，投资者及相关人士均应对此保持足够认识，并且应当理解 计划、预测与承诺之间的差异。请投资者认真阅读本报告全文，并注意公司 可能存在的技术与产品开发风险、人才流失风险、行业竞争风险、管理风险、 收款及经营业绩的季节性波动风险、减值风险等，敬请广大投资者注意投资 风险。详见本报告"第三节 管理层讨论与分析"中"十、公司 ...

Group 1 - The core point of the article is that Weining Health Technology Group Co., Ltd. has won a bid for a project related to medical insurance traceability codes in Jiaxing City, with a contract amount of 207,200 [1][2] - The project was announced by the Jiaxing City Nanhu District Health and Health Bureau on August 8, 2025 [2] - Weining Health has made investments in 50 companies and participated in 9,713 bidding projects, indicating its active engagement in the industry [1] Group 2 - The company holds 124 trademark registrations, 510 patents, and 511 copyrights, showcasing its strong intellectual property portfolio [1] - Weining Health has obtained 20 administrative licenses, reflecting its compliance and operational capabilities within the healthcare sector [1]

Group 1 - The internet insurance sector experienced a decline of 1.11%, ranking among the top losers in the concept sector, with *ST Gao Hong hitting the limit down [1] - Major stocks in the internet insurance sector that saw significant declines include Dongfang Caifu, Xinzhisoft, and China Life, while seven stocks recorded gains, with Qipilang, Aishida, and Jiayun Technology leading the increases at 3.21%, 1.80%, and 1.51% respectively [1][2] - The concept sector saw a net outflow of 3.946 billion yuan, with 13 stocks experiencing net outflows, and six stocks seeing outflows exceeding 50 million yuan, led by Dongfang Caifu with a net outflow of 2.978 billion yuan [1] Group 2 - The top net inflow stocks in the internet insurance concept include Jinzhen Co., Tongfang Co., and Jiao Dian Technology, with net inflows of 51.0932 million yuan, 26.9891 million yuan, and 26.6014 million yuan respectively [1] - The stocks with the highest net outflows include Dongfang Caifu, China Ping An, Weining Health, and China Life, with net outflows of 2.977 billion yuan, 710.6 million yuan, 106.98 million yuan, and 84.8647 million yuan respectively [1][2] - The trading activity in the sector shows that *ST Gao Hong had a decline of 4.91% with a turnover rate of 0.06%, while stocks like Yuheng Pharmaceutical and Jiayun Technology had increases of 0.80% and 1.51% respectively [2]

Market Overview - On August 19, the AI medical sector experienced a slight decline of 0.11%, with Yaobai Technology leading the drop [1] - The Shanghai Composite Index closed at 3727.29, down 0.02%, while the Shenzhen Component Index closed at 11821.63, down 0.12% [1] Stock Performance - Key stocks in the AI medical sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 5.12% to a closing price of 31.40, with a trading volume of 616,700 shares and a transaction value of 1.977 billion [1] - Anbiping (688393) increased by 2.80% to 31.62, with a trading volume of 47,200 shares and a transaction value of 149 million [1] - Yaobai Technology (300725) fell by 3.43% to 48.21, with a trading volume of 196,500 shares and a transaction value of 965 million [2] Capital Flow - The AI medical sector saw a net inflow of 206 million from institutional investors, while retail investors contributed a net inflow of 44.13 million [2] - However, speculative funds experienced a net outflow of 250 million [2] Individual Stock Capital Flow - Seli Medical had a significant net inflow of 356 million from institutional investors, representing 17.99% of its total trading volume [3] - Meinian Health (002044) also saw a net inflow of 121 million from institutional investors, accounting for 12.18% [3] - In contrast, Yaobai Technology experienced a net outflow of 244 million from speculative funds, indicating a negative sentiment [3]

Core Insights - The main business of the company includes medical software research and development, sales, and technical services, providing comprehensive solutions for the healthcare industry [2] - The company's core products are primarily divided into software and services, which account for 77.33% of revenue, and internet healthcare, which accounts for 12.11% [2] - Since its listing in 2011, the company has achieved a cumulative net profit growth of 98.44%, reaching 0.88 billion yuan in the latest fiscal year 2024 [2] Revenue Analysis - In 2020, the company achieved a revenue of 2.267 billion yuan, which increased to 2.782 billion yuan in 2024, although a decline was noted in 2024 [3] Profit Analysis - The company's net profit attributable to shareholders was 491 million yuan in 2020, dropping to 88 million yuan in 2024, indicating significant volatility and an overall downward trend in profit levels [4] Market Performance - Since its IPO, the company's market value has increased by 9.02 times, demonstrating strong growth potential [6] - The peak market value reached 58.552 billion yuan on July 10, 2020, with the stock price rising to 27.44 yuan, but by August 15, the market value had decreased to 23.035 billion yuan, representing a loss of 35.517 billion yuan or 60.66% from its peak [6]

Group 1 - The core stock price of Weining Health as of August 11, 2025, is 10.57 yuan, reflecting an increase of 0.96% from the previous trading day [1] - The trading volume on the same day was 694,083 hands, with a transaction amount of 732 million yuan, and a fluctuation of 2.10% [1] - Weining Health operates in the software development industry, focusing on healthcare information technology, providing software development, sales, and technical services to medical institutions [1] Group 2 - On August 11, the company announced a change in its continuous supervision sponsor representative, with Li Yue replacing Wang Xueping [1] - The company clarified on its investor interaction platform that it has not made any investments in the brain-computer interface field to date [1] Group 3 - Data on capital flow indicates a net outflow of 66.24 million yuan on August 11, accounting for 0.33% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 478 million yuan, representing 2.36% of the circulating market value [1]

（文章来源：证券日报） 证券日报网讯 8月11日晚间，卫宁健康发布公告称，国泰海通证券委派李悦先生接替王雪萍女士继续履 行持续督导职责。 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-061 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特此公告。 卫宁健康科技集团股份有限公司 董 事 会 二〇二五年八月十一日 附件： 李悦先生，现任职于国泰海通证券股份有限公司，保荐代表人， 曾负责或参与的主要项目包括：彤程新材料集团股份有限公司 IPO 项 目、和元生物技术（上海）股份有限公司 IPO 项目、上海浦东发展银 行股份有限公司发行可转债项目、浙江莎普爱思药业股份有限公司非 公开发行股票项目、钜泉广电科技（上海）股份有限公司公开转让项 目、广西绿城水务集团股份有限公司公开发行公司债券项目等。李悦 先生执业记录良好。 卫宁健康科技集团股份有限公司（以下简称"公司"）于近日收 到国泰海通证券股份有限公司（以下简称"国泰海通证券"）出具的 《关于更换卫宁健康科技集团股份有限公司创业板向不特定对象发 行可转换公司债券持续督导之保荐代表人的函》。国泰海通证券作为 公司向不特定对象发行 ...